How many patients do you manage with thyroid eye disease?

On a scale from 1-10 (10 being extremely excited), how excited are you about the Phase 2 and Phase 3 data for Lonigutamab?

What are your thoughts on the current standard of care for thyroid eye disease (TED), including the use of steroids, TEPEZZA, and IL-6 receptor antagonists? How do you decide between medical management and surgical intervention for chronic TED patients, and is there a growing trend toward medication over surgery among oculoplastic surgeons?

How do you view the advancements in TED treatments, particularly the shift from IV to subcutaneous formulations? Could subcutaneous TEPEZZA or other new therapies address unmet needs such as side effects, treatment convenience, and dosing frequency? What are your thoughts on the potential for subcutaneous administration to mitigate side effects like hearing loss?

What is your assessment of Acelyrin’s lonigutamab based on early data, and how do you compare its potential to other IGF-1R inhibitors like TEPEZZA and Viridian’s candidates? Given the small study size, what efficacy and safety benchmarks would be compelling for you in their Phase 3 LONGITUDE trials? How important is first-to-market advantage in this space, and what would convince you to switch treatments?